Funder: Gilead Sciences
Due Dates: January 30, 2026 (LOI, HIV Prevention - INCLUSION Global 2026) | May 4, 2026 (LOI, HIV: RESONATE 2026, BIC/LEN) | June 30, 2026 (LOI, AmBisome topic area)
Funding Amounts: Up to $5,000,000 (INCLUSION Global) or $4,000,000 (RESONATE) total program funds; typical project duration up to 18–24 months; overhead capped at 30%.
Summary: Supports high-impact research on HIV prevention/treatment, AmBisome antifungal therapy, and hepatitis B/C/D care models, with an emphasis on clinical innovation and improved patient outcomes.
Key Information: LOIs must be submitted via Gilead OPTICS; eligibility and scope vary by RFP and topic.